Data Integrity Regulations for Pharma: Recent Trends and Future Direction
White Paper Nov 10, 2020
Driven by globalization and cost-saving demands, the drug-making process has increased in complexity over the last two decades. The separation of key drug development steps such as active pharmaceutical ingredient (API) creation, clinical trials and product manufacturing, often span different locations and can be carried out by various companies across the globe. Therefore, in order to improve traceability of data and improve drug quality, data integrity guidelines are necessary.
Download this whitepaper to learn more about how these regulations are assisting with:
- Addressing quality challenges in drug manufacturing
- Efforts to cope with increasing quality issues
- Supplier strategic efforts to assist in quality improvements
Related White Papers
Download this case study to learn more about how Thermo Scientific Core LIMS™ and Core ELN™ software solutions are supporting efforts to develop the human microbiome into a new modality for drug development.
READ MOREDownload this whitepaper to learn more about the selection of cell models and paints for the process of cellular painting.
READ MORELife science R&D is developing incredible solutions to global problems. But this ground breaking work is often being done with outdated tools that weren't designed with the complexity of life science in mind. Let's explore the core questions that R&D organizations are struggling to answer.
READ MORELike what you just read? You can find similar content on the communities below.
Drug DiscoveryTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
